Abstracts Archive - Page 2014 of 2425 - ACR Meeting Abstracts

Abstract Number: 571 • 2014 ACR/ARHP Annual Meeting
Unraveling the Familial Tendency for Ankylosing Spondylitis in Korea
Hye Won Kim¹, Hye Rim Choe², Won Ik Chang³, Yong-Gil Kim⁴, Bin Yoo⁴, Jin Wook Hur¹, Tae-Hwan Kim⁵, Sungim Lee⁶ and Eun Young Lee⁷, ¹Division of Rheumatology, Department of Internal Medicine, Eulji University of Medicine, Eulji General Hospital, Seoul, South Korea, ²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ³Seoul National University College of Medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Department of Applied Statistics, Dankook University, Yongin, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose : Despite of the evidence of familial aggregation of ankylosing spondylitis (AS), familial tendencies are not fully explored. The purpose of this study was…
Abstract Number: 570 • 2014 ACR/ARHP Annual Meeting
Sleep Disturbances in Korean Patients with Ankylosing Spondylitis Are Associated with Increased Disease Activity
Hye-Jin Jeong¹, Yun Sung Kim², Chang-Nam Son³, Ji-Min Kim³ and Sang-Hyon Kim³, ¹Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Sleep problems have been reported to be more frequent in rheumatic disease than normal population. Other studies indicate various sleep problems have been reported…
Abstract Number: 569 • 2014 ACR/ARHP Annual Meeting
Better Outcomes in Ankylosing Spondylitis: The Synergistic Association Between Exercise and Tumor Necrosis Factor Inhibitors
Sarah L. Patterson¹, John D. Reveille^2,3, MinJae Lee⁴, Michael M. Ward⁵, Mohammad H. Rahbar⁶, Matthew A. Brown⁷, Michael H. Weisman⁸ and Lianne S. Gensler⁹, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁴Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁵Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁶The University of Texas Health Science Center at Houston, Houston, TX, ⁷University of Queensland Diamantina Institute, Brisbane, Australia, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Exercise is an important component of Ankylosing Spondylitis (AS) management. The purpose of this study was to determine if the amount patients exercise associates…
Abstract Number: 567 • 2014 ACR/ARHP Annual Meeting
Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata® Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada
Background/Purpose: Anti-TNF agents namely adalimumab (ADA), etanercept (ETA) and infliximab (INF) are approved for the treatment of signs and symptoms of ankylosing spondylitis. Their efficacy…
Abstract Number: 566 • 2014 ACR/ARHP Annual Meeting
Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Désirée M. van der Heijde¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Jürgen Braun⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany
Background/Purpose The impact of certolizumab pegol (CZP) on clinical and Magnetic Resonance Imaging outcomes in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS)…
Abstract Number: 579 • 2014 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis Do Not Adapt to Their Disease: Evidence from the ‘then Test’ in Patients Treated with TNF-Inhibitors
Ivette Essers¹, Astrid Van Tubergen^1,2, Jurgen Braun³, Xenofon Baraliakos³, Frank Heldmann³ and Annelies Boonen^4,5, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Although never formally studied, rheumatologists feel that patients with ankylosing spondylitis (AS) tend to adjust to their disease. Response shift is one of the…
Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Jürgen Braun¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Desiree van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
Abstract Number: 568 • 2014 ACR/ARHP Annual Meeting
Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Susana Holgado¹, Maria Lourdes Mateo¹, Juana Sanint¹, Anne Riveros-Frutos², Jeronima Cañellas¹, Xavier Tena¹ and Alejandro Olivé Marqués¹, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Secondary amyloidosis (AA) is a disorder caused by deposition of insoluble amyloid A fibrils in different tissues and organs. It is a rare and…
Abstract Number: 550 • 2014 ACR/ARHP Annual Meeting
Secukinumab, an Anti–Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Vibeke Strand¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, P. Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵University of California San Diego, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Psoriatic arthritis (PsA) has a significant adverse effect on patients’ health-related quality of life (HRQoL), affecting their physical and emotional functioning and psychological health.…
Abstract Number: 549 • 2014 ACR/ARHP Annual Meeting
Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis
Philip J. Mease¹, Mark C. Genovese², Alex Mutebi³, Hilary Wilson⁴, Dennis Revicki⁴, Ngozi Erondu⁵, Ajay Nirula⁵, JingYuan Feng⁵ and Hema Viswanathan⁶, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³Global Health Economics, Amgen Inc, Thousand Oaks, CA, ⁴Outcomes Research, Evidera, Bethesda, MD, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, Amgen Inc, Thousand Oaks, CA
Background/Purpose: The Psoriasis Symptom Inventory (PSI) is an 8-item patient-reported outcome measure of psoriasis symptom severity. Data from a Phase 2 study of Brodalumab in…
Abstract Number: 548 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Arthur Kavanaugh¹, Maurizio Cutolo², Philip J. Mease³, Dafna D. Gladman⁴, Adewale O. Adebajo⁵, Juan Gomez-Reino⁶, Jürgen Wollenhaupt⁷, Georg A. Schett⁸, Eric Lespessailles⁹, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher Edwards¹¹ and Charles A. Birbara¹², ¹University of California San Diego, La Jolla, CA, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁷Teaching Hospital of the University of Hamburg, University of Hamburg, Hamburg, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 547 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical and Imaging Characteristics of Axial Psoriatic Arthritis and Axial Spondyloarthritis
Neha Garg¹, Abhijeet Danve², Kiana Vakil-Gilani³ and Atul A. Deodhar⁴, ¹Arthritis & Rheumatic Diseases, Oregon Health and Sciences University, Portland, OR, ²Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³OHSU, Portland, OR, ⁴Oregon Health and Science University, Portland, OR
Background/Purpose Few studies have compared the clinical and imaging (x-ray and MRI) characteristics between axial psoriatic arthritis (axPsA) and axial spondyloarthritis patients without psoriasis (axSpA).…
Abstract Number: 546 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression
Deepak R. Jadon¹, Gavin Shaddick², William Tillett¹, Graham Robinson³, Charlotte Cavill¹, Nicola Waldron¹, Eleanor Korendowych¹ and Neil J McHugh⁴, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Royal United Hospital, Bath, United Kingdom, ⁴Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Psoriatic arthritis mutilans (PAM) is a rare extreme subtype of psoriatic arthritis (PsA). Our objectives were to: (1) compare clinical characteristics of PsA patients…
Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Philip J. Mease¹, Roy Fleischmann², Jurgen Wollenhaupt³, Atul A. Deodhar⁴, Dafna D. Gladman⁵, Bengt Hoepken⁶, Luke Peterson⁷ and Désirée M. van der Heijde⁸, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Oregon Health and Sciences University, Portland, OR, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶UCB Pharma, Monheim, Germany, ⁷Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].